Testing for biomarkers associated with the earliest FDA‐approved agents (2013–2017) for non‐squamous NSCLC (EGFR, ALK, ROS1, and BRAF) were reported by 97% of respondents, with no difference between community versus academic oncologists, or generalists versus specialists. Here, BRAF is linked to non-small cell lung carcinoma.